Status:
COMPLETED
Use of Ranibizumab With Mitomycin C During Trabeculectomy
Lead Sponsor:
University of Colorado, Denver
Collaborating Sponsors:
Genentech, Inc.
Conditions:
Glaucoma
Eligibility:
All Genders
21+ years
Phase:
PHASE1
PHASE2
Brief Summary
The purpose of the study is to study the safety of the combination of ranibizumab and MMC vs monotherapy MMC vs intravitreal ranibizumab injection in patients with glaucoma.
Detailed Description
A common problem after undergoing trabeculectomy surgery to create a bleb (blister or bubble) to reduce intraocular pressure, is scarring of the opening. This scarring prevents fluid drainage and inte...
Eligibility Criteria
Inclusion
- glaucoma
- undergoing trabeculectomy
- 21 years of age or older
Exclusion
- pregnancy or lactation
- any condition the investigator believes would impose a significant hazard to the patient if investigational therapy were initiated
- history of ocular surface disease
- cataract surgery in the past 6 months
- history of active inflammatory, infectious or idiopathic keratitis
Key Trial Info
Start Date :
April 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2014
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00661583
Start Date
April 1 2008
End Date
September 1 2014
Last Update
October 13 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rocky Mountain Lions Eye Institute
Aurora, Colorado, United States, 80045